Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

Phlebotomy is when someone uses a needle to take blood from your vein. It’s also called a blood draw or venipuncture. WebMD explains the process, risks, and side effects.

Healthcare has seen an unprecedented surge in worker demand in recent years. There’s a call for doctors, nurses, and ...

Blake Learns to Draw Blood with Midwest Technical Institute’s Phlebotomy Program Blake gets a lesson in phlebotomy at MTI. Phlebotomists work in a variety of medical ...

Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia ...

Rusfertide reduces or eliminates phlebotomy needs in polycythemia vera, improving quality of life and symptom control. The VERIFY trial showed 77% clinical response with rusfertide, compared to 33% in ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Rusfertide significantly reduced phlebotomy needs in PV patients, with 76.9% achieving clinical response versus 32.9% in the placebo group. The therapy maintained hematocrit levels below 45% in 62 ...

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control ...

Midwest Technical Institute’s Phlebotomy Program Phlebotomists work in a variety of medical facilities and perform laboratory ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...